CD27/NF-kB Reporter-Jurkat Recombinant Cell Line

Products from BPS Bioscience require a minimum order value above 400€

Applications: Screen for agonists or antagonists of CD27-CD70 signaling in a physiologically relevant cellular context Characterize T cell-mediated immune responses of CD27 and its interaction with CD70

Background: CD27 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the T cell co-stimulatory receptors OX40, 4-1BB and herpesvirus entry mediator (HVEM). CD27 is expressed on various types of T cells, B cells and a subset of natural killer cells. It activates NF-κB and MAPK/JNK signaling upon interaction with its TNF-like ligand, CD70, which is expressed by numerous tumor cells. Adaptor proteins TRAF2 and TRAF5 can also stimulate CD27 signaling. Activation of CD27 leads to lymphoid proliferation, differentiation, apoptosis, and the induction of long-term memory. The CD27/CD70 pathway is a key target for the development of treatments for cancer and inflammatory diseases.

Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NF-kB response elements with constitutive expression of human CD27 (also known as Tumor Necrosis Factor Receptor Superfamily Member 7, TNFRSF7, and T14, Genbank Accession #BC012160)

Host Cell Line: Jurkat

Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination.

Storage Stability: Store in liquid nitrogen immediately upon receipt

Supplied As: Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: BSL-1

• Artikelnummer: BPS79509
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 79509
• Verpackungseinheit: 2 vials
• Mengeneinheit: PAK
• Wirt: Human